Prophase Labs Inc (PRPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2000 | 06-2000 | 03-2000 | 12-1999 | 09-1999 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 10,100 | 8,210 | 12,100 | 13,990 | 13,400 |
| Receivables | 3,830 | 1,860 | 2,230 | 6,640 | 3,350 |
| Inventories | 7,020 | 6,670 | 6,010 | 6,170 | 7,130 |
| Other current assets | 1,270 | 3,990 | 3,950 | 3,870 | 4,930 |
| TOTAL | $22,220 | $20,730 | $24,290 | $30,670 | $28,810 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 830 | 780 | 490 | 640 | 600 |
| TOTAL | $830 | $780 | $490 | $640 | $600 |
| Total Assets | $25,240 | $23,630 | $26,760 | $33,270 | $30,830 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 490 | 460 | 310 | 390 | 190 |
| Accrued Expenses | 2,680 | 2,290 | 3,920 | 6,350 | 2,070 |
| Other current liabilities | 910 | 240 | 240 | 300 | 560 |
| TOTAL | $4,090 | $2,990 | $4,470 | $7,050 | $2,830 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 361 | 0 | 0 | 0 | 0 |
| TOTAL | $330 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $4,420 | $2,990 | $4,470 | $7,050 | $2,830 |
| Shareholders' Equity | |||||
| Common Shares | 8 | 8 | 7 | 7 | 7 |
| Retained earnings | 16,980 | 16,870 | 18,520 | 22,440 | 23,700 |
| Other shareholders' equity | -48 | -38 | -37 | -37 | -37 |
| TOTAL | $20,810 | $20,640 | $22,290 | $26,210 | $28,000 |
| Total Liabilities And Equity | $25,230 | $23,630 | $26,760 | $33,260 | $30,830 |